Considering the lack of available effective therapies for patients with AML with TP53 mutations and/or complex karyotype, the results of this clinical trial suggest that TP-0903 may offer insight and serve as a benchmark for the development of future agents leveraging similar strategies or scaffolds, which could improve outcomes for patients with TP53 mutant and/or complex karyotype AML. Here, TP53 is linked to acute myeloid leukemia.